Pneumonitis with combined immune checkpoint inhibitors and chemoradiotherapy in locally advanced non-small-cell lung cancer: a systematic review and meta-analysis.

Abstract

Aims: This study systematically evaluated cases of pneumonitis following combined immune checkpoint inhibitors (ICI) and chemoradiotherapy (CRT) for locally advanced non-small-cell lung cancer (LA-NSCLC). Methods: Studies from Embase, PubMed and the Cochrane Library on patients with LA-NSCLC who received CRT and ICIs were reviewed. The primary outcomes were rates of all-grade, grade 3-5 and grade 5 pneumonitis. Results: Overall, 35 studies involving 5000 patients were enrolled. The pooled rates of all-grade, grade 3-5 and grade 5 pneumonitis were 33.0% (95% CI: 23.5-42.6), 6.1% (95% CI: 4.7-7.4) and 0.8% (95% CI: 0.3-1.2), respectively, with 7.6% of patients discontinuing ICIs because of pneumonitis. Conclusion: The incidence rates of pneumonitis following combined CRT and ICIs for LA-NSCLC were acceptable. However, the pulmonary toxicity of concurrent CRT and nivolumab plus ipilimumab should be noted.

• Authors: Linlin Yang, Butuo Li, Yiyue Xu, Bing Zou, Bingjie Fan, Chunni Wang, Linlin Wang
• Journal: Future oncology (London, England) (Future Oncol) Vol. 19 Issue 16 Pg. 1151-1160 (May 2023) ISSN: 1744-8301 [Electronic] England
• PMID: 37293787 (Publication Type: Meta-Analysis, Systematic Review, Journal Article, Review)

Chemical References

• Immune Checkpoint Inhibitors

Topics

• Humans
• Carcinoma, Non-Small-Cell Lung (drug therapy)
• Immune Checkpoint Inhibitors (adverse effects)
• Lung Neoplasms (drug therapy)
• Pneumonia (chemically induced, epidemiology)
• Chemoradiotherapy (adverse effects)